Ablynx « Terug naar discussie overzicht

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
[verwijderd]
0
[verwijderd]
0
Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
[verwijderd]
0
Op zoek naar overnamekandidaten in de biotech zoals Ablynx of Tigenix.
Conatus pharmaceuticals lijkt een overnameprooi te gaan worden beurskrant.com/2018/03/06/stijgingspo...
3 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
911,93  +0,02  +0,00%  15:50
 Germany40^ 18.713,70 -0,15%
 BEL 20 3.962,48 -0,45%
 Europe50^ 5.076,74 -0,04%
 US30^ 39.500,40 +0,13%
 Nasd100^ 18.222,90 +0,10%
 US500^ 5.229,59 +0,12%
 Japan225^ 38.435,00 +0,64%
 Gold spot 2.350,47 +0,59%
 EUR/USD 1,0814 +0,22%
 WTI 78,16 -1,31%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

JUST EAT TAKE... +7,32%
Alfen N.V. +4,71%
BAM +4,18%
Air France-KLM +4,02%
PROSUS +3,75%

Dalers

VIVORYON THER... -3,64%
ASR Nederland -2,92%
IMCD -2,84%
NN Group -2,12%
JDE PEET'S -1,91%